SG10202000644TA - Improved Stem Cell Composition - Google Patents

Improved Stem Cell Composition

Info

Publication number
SG10202000644TA
SG10202000644TA SG10202000644TA SG10202000644TA SG10202000644TA SG 10202000644T A SG10202000644T A SG 10202000644TA SG 10202000644T A SG10202000644T A SG 10202000644TA SG 10202000644T A SG10202000644T A SG 10202000644TA SG 10202000644T A SG10202000644T A SG 10202000644TA
Authority
SG
Singapore
Prior art keywords
stem cell
cell composition
improved stem
improved
composition
Prior art date
Application number
SG10202000644TA
Other languages
English (en)
Inventor
Silviu Itescu
Paul Simmons
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901247A external-priority patent/AU2014901247A0/en
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of SG10202000644TA publication Critical patent/SG10202000644TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG10202000644TA 2014-04-07 2015-04-07 Improved Stem Cell Composition SG10202000644TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2014901247A AU2014901247A0 (en) 2014-04-07 Improved stem cell composition

Publications (1)

Publication Number Publication Date
SG10202000644TA true SG10202000644TA (en) 2020-03-30

Family

ID=53724311

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202000644TA SG10202000644TA (en) 2014-04-07 2015-04-07 Improved Stem Cell Composition
SG11201607925SA SG11201607925SA (en) 2014-04-07 2015-04-07 Improved stem cell composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201607925SA SG11201607925SA (en) 2014-04-07 2015-04-07 Improved stem cell composition

Country Status (9)

Country Link
US (3) US10400218B2 (ko)
EP (2) EP3129468B1 (ko)
JP (3) JP6882161B2 (ko)
KR (2) KR102405663B1 (ko)
CN (2) CN113337462A (ko)
AU (5) AU2015243575B2 (ko)
CA (1) CA2944262C (ko)
SG (2) SG10202000644TA (ko)
WO (1) WO2015155187A1 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155187A1 (en) * 2014-04-07 2015-10-15 Mesoblast International Sarl Improved stem cell composition
WO2015189063A1 (en) * 2014-06-10 2015-12-17 Mesoblast International Sàrl Treatment of immune disorders
JP6231709B1 (ja) * 2016-05-31 2017-11-15 シスメックス株式会社 蛍光画像分析装置および分析方法
EP3619294A1 (en) * 2017-05-04 2020-03-11 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
WO2022020210A1 (en) 2020-07-18 2022-01-27 Ossium Health, Inc. Permeation of whole vertebral bodies with a cryoprotectant using vacuum assisted diffusion
CA3195653A1 (en) 2020-10-14 2022-04-21 Ossium Health, Inc. Systems and methods for extraction and cryopreservation of bone marrow
CN117279650A (zh) 2020-12-18 2023-12-22 奥瑟姆健康公司 细胞治疗方法
WO2024121821A1 (en) * 2022-12-09 2024-06-13 Mesoblast International Sarl Conditioned media and use of the same
WO2024121820A1 (en) * 2022-12-09 2024-06-13 Mesoblast International Sarl Pre-licensed composition and cell culture methods
WO2024121818A1 (en) * 2022-12-09 2024-06-13 Mesoblast International Sarl Method of treating heart failure in subjects with persistent inflammation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
AU5734998A (en) 1997-01-10 1998-08-03 Life Technologies, Inc. Embryonic stem cell serum replacement
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AU2005209688A1 (en) * 1999-07-07 2005-10-06 Angioblast Systems, Inc. Mesenchymal precursor cell
EP1600511A4 (en) * 2003-02-19 2006-08-23 Dnavec Research Inc METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESS
CA2581237C (en) * 2004-09-24 2018-11-06 Angioblast Systems, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc)
DK1869165T3 (en) 2005-04-12 2016-02-01 Mesoblast Inc Isolation of Adult Multipotent Cells by Tissue-Specific Alkaline Phosphate
WO2007122233A1 (en) * 2006-04-25 2007-11-01 Vrije Universiteit Brussel Preparation of mesenchymal progenitor cells, particularly osteogenic progenitor cells
CN101407790B (zh) * 2008-10-30 2010-09-29 浙江大学 一种增强人骨髓间充质干细胞旁分泌能力的处理方法
EP2258413A1 (en) * 2009-06-04 2010-12-08 Université Catholique de Louvain Multi-dimensional biomaterial and method for producing the same.
CN102899293A (zh) * 2012-11-01 2013-01-30 上海市肺科医院 促血管生成素1基因修饰的间充质干细胞、及其构建方法与应用
EP3879743A1 (en) * 2013-12-18 2021-09-15 IDAC Holdings, Inc. Methods, apparatus and systems for interference management in a full duplex radio system
WO2015155187A1 (en) 2014-04-07 2015-10-15 Mesoblast International Sarl Improved stem cell composition

Also Published As

Publication number Publication date
KR102405663B1 (ko) 2022-06-07
JP2017512842A (ja) 2017-05-25
JP2021080272A (ja) 2021-05-27
US11312941B2 (en) 2022-04-26
AU2018200619B2 (en) 2020-01-02
AU2022200640B2 (en) 2024-02-15
US10400218B2 (en) 2019-09-03
EP3129468A1 (en) 2017-02-15
CA2944262C (en) 2023-08-01
AU2022200640A1 (en) 2022-02-24
US20170107495A1 (en) 2017-04-20
SG11201607925SA (en) 2016-10-28
JP2023021279A (ja) 2023-02-10
CN106459913B (zh) 2021-05-18
AU2020202214B2 (en) 2021-11-18
AU2015243575A1 (en) 2016-10-13
KR20220080023A (ko) 2022-06-14
CN106459913A (zh) 2017-02-22
EP4137560A1 (en) 2023-02-22
WO2015155187A1 (en) 2015-10-15
EP3129468B1 (en) 2022-09-21
JP7196216B2 (ja) 2022-12-26
US20190345452A1 (en) 2019-11-14
AU2018200619B9 (en) 2020-05-07
AU2018200619A1 (en) 2018-02-15
KR102577698B1 (ko) 2023-09-12
US20230030428A1 (en) 2023-02-02
CA2944262A1 (en) 2015-10-15
KR20160145066A (ko) 2016-12-19
AU2024203197A1 (en) 2024-05-30
AU2020202214A1 (en) 2020-04-16
CN113337462A (zh) 2021-09-03
JP6882161B2 (ja) 2021-06-02
AU2015243575B2 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
IL274903A (en) cell
ZA201901336B (en) Improved t cell compositions
SG10202000644TA (en) Improved Stem Cell Composition
LT3157504T (lt) Kamienines ląsteles stimuliuojančios kompozicijos
GB201410905D0 (en) Composition
GB201404178D0 (en) Composition
GB201403017D0 (en) Composition
GB201414910D0 (en) Composition
GB201403561D0 (en) Composition
GB201414555D0 (en) Composition
GB201410493D0 (en) Composition
HUE042287T2 (hu) Lítium-kén cella
SG10201403640XA (en) Stem cells
GB201404390D0 (en) Composition
GB201403550D0 (en) Composition
GB201402648D0 (en) Composition
AU2014901247A0 (en) Improved stem cell composition
GB201416750D0 (en) Cell preparation
GB201410934D0 (en) T cell
GB201412414D0 (en) Composition
GB201412314D0 (en) Composition
GB201402487D0 (en) Composition
GB201401510D0 (en) Composition